143 related articles for article (PubMed ID: 38256570)
1. The Application of Existing Risk Assessment Models (RAMS) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin Lymphoma.
Ma'koseh M; Abufara A; Albaghdadi D; Ghalayni R; Abdel-Razeq S; Alzughali E; Abdel Rahman F; Alhalaseh Y; Halahleh K; Abdel-Razeq H
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256570
[No Abstract] [Full Text] [Related]
2. The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma.
Kirkizlar O; Alp Kirkizlar T; Umit EG; Asker I; Baysal M; Bas V; Gulsaran SK; Demirci U; Demir AM
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):542-547. PubMed ID: 32245743
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice.
Rupa-Matysek J; Brzeźniakiewicz-Janus K; Gil L; Krasiński Z; Komarnicki M
Cancer Med; 2018 Jul; 7(7):2868-2875. PubMed ID: 29761831
[TBL] [Abstract][Full Text] [Related]
4. The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma.
Abdel-Razeq H; Ma'koseh M; Mansour A; Bater R; Amarin R; Abufara A; Halahleh K; Manassra M; Alrwashdeh M; Almomani M; Zmaily M
Clin Appl Thromb Hemost; 2021; 27():10760296211045908. PubMed ID: 34590497
[TBL] [Abstract][Full Text] [Related]
5. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma.
Rupa-Matysek J; Gil L; Barańska M; Dytfeld D; Komarnicki M
Oncotarget; 2018 Apr; 9(30):21190-21200. PubMed ID: 29765530
[TBL] [Abstract][Full Text] [Related]
6. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
[TBL] [Abstract][Full Text] [Related]
7. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
8. Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma.
Bastos-Oreiro M; Ortiz J; Pradillo V; Salas E; Marínez-Laperche C; Muñoz A; Buño I; Diéz-Martin JL; Soria JM; Pascual Izquierdo C
Cancer Med; 2021 Nov; 10(21):7585-7592. PubMed ID: 34598309
[TBL] [Abstract][Full Text] [Related]
9. The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients.
Abdel-Razeq H; Ma'koseh M; Abdel-Razeq R; Amarin R; Abufara A; Mansour R; Manasrah M; Al-Rwashdeh M; Bater R
Front Oncol; 2021; 11():677776. PubMed ID: 34123847
[TBL] [Abstract][Full Text] [Related]
10. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution.
de Armas S; Huertas-Ayala C; Chan RY; Chi YY; Huh WW; Termuhlen A; Gaynon PS; Kovach AE; Doan A
Pediatr Blood Cancer; 2022 May; 69(5):e29601. PubMed ID: 35187850
[TBL] [Abstract][Full Text] [Related]
11. OC-07 - Decoding risk for thromboembolic events in lymphoma patients.
Antic D; Milic N; Todorovic M; Bila J; Andjelic B; Djurasinovic V; Sretenovic A; Vukovic V; Jelicic J; Nikolovski S; Mihaljevic B
Thromb Res; 2016 Apr; 140 Suppl 1():S171. PubMed ID: 27161679
[TBL] [Abstract][Full Text] [Related]
12. Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.
Bamias A; Tzannis K; Dimitriadis I; Tsironis G; Papatheorodidi AM; Tsiara A; Fragkoulis C; Xirokosta A; Barbarousi D; Papadopoulos G; Zakopoulou R; Varkarakis I; Mitsogiannis I; Adamakis I; Alamanis C; Stravodimos K; Papatsoris AG; Dellis AE; Drivalos A; Ntoumas K; Matsouka H; Halvatsiotis P; Raptis A; Gerotziafas GT; Dimopoulos MA
Clin Genitourin Cancer; 2020 Aug; 18(4):e457-e472. PubMed ID: 32007440
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study.
Makiyama J; Imaizumi Y; Watanabe H; Fujioka M; Chiwata M; Kitanosono H; Nakashima J; Miyazaki Y; Yoshida S
Intern Med; 2021 Mar; 60(5):709-718. PubMed ID: 33087662
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, Patterns, and Predictors of Venous Thromboembolic Events in Patients Undergoing Salvage Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Lymphomas.
Ma'koseh M; Alrwashdeh M; Abdel-Razeq N; Alfar R; Edaily S; Bater R; Zmaily M; Almomani M; Abdel-Razeq H
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):323-329. PubMed ID: 37363978
[TBL] [Abstract][Full Text] [Related]
15. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
[TBL] [Abstract][Full Text] [Related]
16. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
[TBL] [Abstract][Full Text] [Related]
17. Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction models.
Dharmavaram G; Cao S; Sundaram S; Ayyappan S; Boughan K; Gallogly M; Malek E; Metheny L; Tomlinson B; Otegbeye F; Lazarus HM; Cooper B; Fu P; de Lima M; Caimi PF
Am J Hematol; 2020 Aug; 95(8):918-926. PubMed ID: 32311162
[TBL] [Abstract][Full Text] [Related]
18. Investigation of two general venous thromboembolism risk-stratification models in predicting venous thromboembolic events in TB patients.
Sharif-Kashani B; Azimi M; Tabarsi P; Sadr M; Shirzadi S
Int J Mycobacteriol; 2022; 11(1):83-87. PubMed ID: 35295028
[TBL] [Abstract][Full Text] [Related]
19. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract][Full Text] [Related]
20. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.
Winter A; Liu N; Surinach A; Fanale M; Yu KS; Narkhede M
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):527-534. PubMed ID: 37121857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
